Exhibit 107.1
Form S-8
(Form Type)
VIRIDIAN THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title(1) | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan (the “2016 ESPP Plan”) | Other(2) | 539,861 | $18.37(2) | $9,914,548(2) | $147.60 per $1,000,000 | $1,463.39 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on September 1, 2023 | Other(3) | 31,000 | $19.11(3) | $592,410 | $147.60 per $1,000,000 | $87.44 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on September 1, 2023 | Other(3) | 75,000 | $19.11(3) | $1,433,250 | $147.60 per $1,000,000 | $211.55 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023 | Other(3) | 1,259,400 | $13.02(3) | $16,397,388 | $147.60 per $1,000,000 | $2,420.25 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023 | Other(3) | 474,400 | $13.02(3) | $6,176,688 | $147.60 per $1,000,000 | $911.68 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023 | Other(3) | 206,200 | $13.02(3) | $2,684,724 | $147.60 per $1,000,000 | $396.27 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023 | Other(3) | 62,000 | $13.02(3) | $807,240 | $147.60 per $1,000,000 | $119.15 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on November 1, 2023 | Other(3) | 62,000 | $12.60(3) | $781,200 | $147.60 per $1,000,000 | $115.31 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on January 2, 2024 | Other(3) | 62,000 | $22.35(3) | $1,385,700 | $147.60 per $1,000,000 | $204.53 | |||||||
| Equity | Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on February 1, 2024 | Other(3) | 30,000 | $20.00(3) | $600,000 | $147.60 per $1,000,000 | $88.56 | |||||||
| Total Offering Amounts | $40,773,148 | $6,018.13 | ||||||||||||
| Total Fee Offsets | $0.00 | |||||||||||||
| Net Fee Due | $6,018.13 | |||||||||||||
| (1) | Represents (i) 539,861 shares of common stock of Viridian Therapeutics, Inc. (the “Registrant”) issuable through the 2016 ESPP Plan; (ii) 2,262,000 shares of common stock of the Company issuable pursuant to the Stock Option Inducement Awards granted on September 1, 2023, October 30, 2023, November 1, 2023, January 2, 2024 and February 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933 (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”), also includes additional shares of common stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 ESPP Plan and the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions. |
| (2) | Estimated solely for calculating the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act, on the basis of the average of the high and low sale prices of the shares of common stock of the Company on The Nasdaq Capital Market on February 23, 2024, within five business days prior to filing. |
| (3) | Based on the exercise price on the date of grant. |
